Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Where Will Moderna Be in 10 Years?

The NIH disagrees with Moderna over who deserves credit for inventing the company's COVID-19 vaccine.

Why Moderna Is Fighting Its Biggest Customer

AstraZeneca

Moderna Inc (NASDAQ: MRNA) announced data from the AstraZeneca Plc (NASDAQ: AZN)-led Phase 2 (EPICCURE) study evaluating AZD8601 in patients undergoing coronary artery bypass grafting (CABG). AZD8601 is an mRNA therapeutic that encodes for vascular endothelial growth factor-A (VEGF-A).

AstraZeneca, Moderna Shares Early Cut Data For mRNA Candidate In Heart Failure

Moderna Inc. MRNA, -0.03% said Friday that a booster dose for its COVID-19 vaccine has been authorized by Health Canada for use in people at least 18 years old, at least six months after the completion of the primary two-dose regimen. Last month, U.S. regulators had signed off on extending boosters to Americans who got the Moderna or Johnson & Johnson JNJ, -0.46% vaccine, and said eligible people can get a brand different from the shots they originally received.

Moderna's COVID-19 vaccine boosters OK's by Health Canada

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Health Canada Authorizes Booster Dose of Moderna's COVID-19 Vaccine in Individuals 18 Years of Age and Older

Health Canada Authorizes Booster Dose of Moderna's COVID-19 Vaccine in Individuals 18 Years of Age and Older

These are Insider's biggest healthcare stories for November 15.

Why Moderna's betting big on gene editing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery

Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery

Moderna Inc (NASDAQ: MRNA) announced interim data from Phase 1 study of mRNA-2752 (Triplet) in patients with accessible solid tumors and lymphomas.  The data showed that the mRNA Triplet program given in combination with AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) was tolerated at all dose levels and elicited evidence of anti-tumor activity.

Moderna Posts Interim Data From mRNA Triplet Program In Solid Tumors

Noubar Afeyan launched 70 companies by pushing researchers to ask what if their craziest ideas were true. With $17 billion and a model of “parallel entrepreneurship,” he can fund a lot of wild notions.

The Billionaire Chairman Of Vaccine Maker Moderna Wants To Reinvent Scientific Entrepreneurship

The shares of Moderna Inc (NASDAQ: MRNA) have received a $404 price target from Barclays. These are the details.

Moderna (MRNA) Stock: $404 Price Target From Barclays

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Triplet Program at 2021 SITC Annual Meeting

Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Triplet Program at 2021 SITC Annual Meeting

Moderna won't win authorization for its COVID-19 vaccine in kids as soon as it hoped.

How Serious Are Moderna's FDA Delays?

Negative headlines have come in rapid fire for the company in recent weeks—and it dramatically missed sales estimates for the third quarter.

Moderna Stock Falls Back to Earth as Questions Mount

Moderna Inc (NASDAQ: MRNA) defended using its COVID-19 vaccine, saying the protection it offers outweighs the risk of myocarditis seen in a small number of young men who received the shot, reports CNBC. The FDA last week said it requires more time to decide whether to authorize Moderna's vaccine for use in children ages 12 to 17.

Moderna Says COVID-19 Vax Associated With Fewer Cases Than Pfizer's, But Higher Inflammatory Heart Conditions

Moderna defended the use of its Covid vaccine, saying the protection it offers against severe disease, hospitalization and death outweighs the risk of myocarditis.

Moderna says Covid vaccine has fewer breakthrough cases than Pfizer's, but higher myocarditis rates in young men

The director of the U.S. NIH said it will fight to have its scientists recognized on a key patent for Moderna's vaccine, which the biotech insists it developed alone.

Government Legal Battle Looms Over Who Should Take Credit For Moderna Vaccine

BioNTech SE

Novavax

For most of the past two years, all the focus has been on the coronavirus, but these biotechs have big plans to develop inoculations against other diseases, too.

3 Vaccine Stocks With Big Opportunities Outside of COVID-19

Over the last five trading sessions, Moderna's stock has cratered 30%, dropping from $350 a share all the way down to $240. The steep fall came after the Cambridge, Massachusetts-based company reported disappointing quarterly results that shocked Wall Street and revised down its forward guidance.

Moderna Stock Could Have a Lot Further to Fall After Disasterous Earnings

Moderna Inc's (NASDAQ: MRNA) ongoing feud with the National Institutes of Health (NIH) over COVID-19 vaccine patents has spilled into the open. Both parties are in dispute over who deserves credit for inventing the central component of the Company's COVID-19 vaccine.

Moderna, NIH At Odds Over Who Invented The Biotech's COVID-19 Shot: NYT

The European Medicines Agency expects to decide in about two months whether to allow the use of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine in children aged six to 11 years. "The current timeline for evaluation foresees an opinion in approximately two months unless supplementary information or analysis is needed," the EMA said

EU's Decision On Moderna's COVID-19 Shot For Younger Kids Expected In Two Months

Amazon

DoorDash

Johnson & Johnson

Pfizer

Regeneron Pharmaceuticals

AMC Entertainment

Cisco Systems

Zoom Video

More than a year and a half into the Covid-19 pandemic, the world is changing. More people are returning to the office after months of working at home and restaurants have reopened.

10 Stocks Post-Pandemic: What to Consider, Keep and Run From

Bath and Body Works

Devon Energy

Ford Motor Company

Fortinet

Gartner

NVIDIA

The S&P 500 logged in eight consecutive gains, representing its longest winning streak since 2017, and closed above the 4,700 milestone for the first time ever.

7 Stocks With Triple-Digit Gains Powering S&P 500 ETF

Shares of Moderna Inc. MRNA, +3.24% gained 0.5% in premarket trading on Tuesday after the company said it is seeking an update to the conditional authorization of its COVID-19 vaccine in Europe so that it includes children between the ages of 6 and 11 years old. Moderna said earlier this month that it will delay filing for authorization in this age group in the U.S. until the Food and Drug Administration's review of the myocarditis risk in teens is resolved, likely by January.

Moderna files for authorization for its COVID-19 vaccine in young children in Europe

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Files to Expand the Conditional Marketing Authorization for its COVID-19 Vaccine in the European Union to Include Children Ages 6-11 Years

Moderna Files to Expand the Conditional Marketing Authorization for its COVID-19 Vaccine in the European Union to Include Children Ages 6-11 Years

Moderna stock declined by about 30% over the last week (five trading days) following the company's weaker than expected Q3 2021 results. While Moderna's revenue for Q3 grew by almost 13% sequentially to about $4.97 billion, they missed consensus estimates by almost 20%.

News for Moderna Stock (MRNA)